Gritstone Oncology Announces Pricing of Initial Public Offering
September 27 2018 - 9:30PM
Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing
of its initial public offering of 6,666,667 shares of common stock
at a public offering price of $15.00 per share, before underwriting
discounts and commissions. All of the shares of common stock are
being offered by Gritstone Oncology. In addition, Gritstone
Oncology has granted the underwriters a 30-day option to purchase
up to an additional 1,000,000 shares of common stock at the initial
public offering price, less the underwriting discounts and
commissions. Gritstone Oncology’s common stock is expected to begin
trading on The Nasdaq Global Select Market on Sept. 28, 2018, under
the ticker symbol “GRTS”. The gross proceeds from the offering,
before deducting underwriting discounts and commissions and other
offering expenses payable by Gritstone Oncology, are expected to be
approximately $100 million, excluding any exercise of the
underwriters’ option to purchase additional shares. The offering is
expected to close on Oct. 2, 2018, subject to the satisfaction of
customary closing conditions.
Goldman Sachs & Co. LLC, Cowen and Company, LLC and Barclays
Capital Inc. acted as joint book-running managers for the offering.
BTIG, LLC acted as lead manager for the offering.
Registration statements relating to the shares being sold in
this offering became effective by the Securities and Exchange
Commission on Sept. 27, 2018. The offering is being made only by
means of a prospectus, copies of which may be obtained, when
available, from: Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, telephone:
1-866-471-2526; Cowen and Company, LLC, c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention:
Prospectus Department, telephone: 1-631-274-2806, or email:
PostSaleManualRequests@broadridge.com; or Barclays Capital Inc.,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: 1-888-603-5847, or email:
Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Gritstone OncologyGritstone Oncology is
developing tumor-specific cancer immunotherapies to fight multiple
cancer types. The company has built its tumor-specific
immunotherapy approach on two key pillars—first, a proprietary
machine learning-based platform, Gritstone EDGE™, which provides a
powerful ability to predict from a routine tumor biopsy the
tumor-specific neoantigens, or TSNA, that are presented on a
patient’s tumor cells; and second, the ability to develop and
manufacture potent immunotherapies utilizing patients’ TSNA to
drive the patient’s immune system to attack and destroy tumors.
Contacts
Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com
Investors:Alexandra SantosWheelhouse Life Science Advisors(510)
871-6161asantos@wheelhouselsa.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024